Core Insights - Ligand Pharmaceuticals has appointed two prominent healthcare investors, Dr. Peter Renehan and Mr. Lee Brown, as Vice Presidents of Investments and Business Development, enhancing its leadership team [1][2] - The company aims to strengthen its investment strategy and capitalize on royalty financing opportunities, which are a key differentiator for Ligand [4] Company Developments - Dr. Renehan previously worked at Blackstone Life Sciences and has experience in healthcare investment banking and corporate strategy [2] - Mr. Brown joins from Third Bridge Group and has a background as a founder and Chief Investment Officer of Reef Knot Capital [2] - Lauren Hay is transitioning to Vice President of Portfolio Strategy and Investments, focusing on optimizing Ligand's existing portfolio and identifying new investment opportunities [3] Strategic Goals - The new appointments are expected to support Ligand's long-term value creation for shareholders by enhancing the company's ability to navigate capital structures and identify undervalued opportunities [4] - The expansion of the leadership team is a response to robust demand for royalty financing transactions, which are integral to Ligand's business model [4] Company Overview - Ligand Pharmaceuticals is a leading royalty aggregator, partnering with biopharmaceutical companies to finance late-stage clinical development programs [5] - The company manages a diversified portfolio of over 100 development and commercial-stage assets, aiming to deliver consistent revenue streams [5] - Ligand also licenses proprietary technologies, such as Captisol® and NITRICIL™, to support drug development across its global partner network [5]

Financial Performance - Ligand Pharmaceuticals reported total GAAP revenue of $268 million for 2025, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [15][16] - Full-year royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products such as FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] - Adjusted EPS increased to $8.13, up 42% year-over-year, indicating strong operating leverage and higher royalty contributions [15][16] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [16][17] - Ohtuvayre reported net sales of $178 million in Q4, with full-year sales of $506 million, marking a strong launch in COPD history [17][34] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17][18] Market Performance - Ligand's royalty portfolio is expected to see a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] - The company anticipates significant commercial opportunities in Japan for FILSPARI, with a sizable market for IgAN [71] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a systematic portfolio management strategy to drive value across partnerships [9][10][22] - The demand for royalty financing has doubled over the last five years, positioning Ligand favorably within the biopharmaceutical royalty financing sector [10][11] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong trial results for QTORIN rapamycin and the successful partnership with Leona Bio for lasofoxifene [36] - The company is optimistic about the upcoming year, expecting multiple catalysts from its late-stage development pipeline [36][31] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company reaffirmed its 2026 financial guidance, expecting adjusted EPS of approximately $8-$9 per share and royalty revenue of $200 million-$225 million [20][21] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][50] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size will increase, focusing on high clinical value assets [58][59]

Financial Data and Key Metrics Changes - Full-year adjusted EPS exceeded original 2025 guidance by more than 30%, with a 42% increase year-over-year [6][7] - Total GAAP revenue for 2025 was $268 million, up from $167 million in 2024, with core revenue reflecting a 43% year-over-year growth at $240 million [15][16] - Royalty revenue grew to $161 million, an increase of 48% year-over-year, driven by products like FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [15][16] Business Line Data and Key Metrics Changes - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total annual sales of $322 million [16][17] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales just under $200 million [17] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [17] Market Data and Key Metrics Changes - The royalty funding market has doubled over the last five years, indicating a growing demand for royalty capital [10][11] - Ligand expects a 23% compound annual growth rate in royalty receipts from 2025 through 2030, driven by contributions across the entire portfolio [12][13] Company Strategy and Development Direction - Ligand is focused on disciplined investments to create new, clinically differentiated product royalty streams and enhance long-term shareholder value [8][9] - The company launched a systematic portfolio management strategy to proactively communicate with partners and identify new investment opportunities [22][23] - Ligand aims to expand its business development efforts and deepen its pipeline, with a strong capital base to support growth initiatives [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and disciplined capital deployment approach, positioning the company for sustained long-term growth [12][13] - The company anticipates significant commercial upside from products like FILSPARI and Ohtuvayre, with ongoing efforts to engage with regulatory bodies for approvals [34][35] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [20] - The company is optimistic about the potential of lasofoxifene and QTORIN rapamycin, with significant market opportunities projected [24][29] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and TZIELD, with robust updates expected in the coming quarters [39][40] Question: Update on monetizing older assets in the portfolio - Management confirmed active engagement in 5 to 10 opportunities for older assets, with potential announcements expected by year-end [43][44] Question: Larger opportunity for TZIELD and peak sales size - Management acknowledged TZIELD's low royalty but emphasized its potential blockbuster status, particularly with the upcoming Stage 3 indication [48][49] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS contribution to 2026 guidance is modest, with a risk-adjusted estimate of $4 million [53][55] Question: Changes in selection criteria for potential partnerships - Management noted that as the portfolio value grows, the average deal size sought will increase, focusing on high clinical value assets [58][59] Question: Market size opportunity for FILSPARI in IgAN and FSGS - Management estimated consensus market size for both indications at around $1 billion, with potential royalties of approximately $90 million for each [70][71]

Financial Performance - In 2025, Ligand Pharmaceuticals achieved total GAAP revenue of $268 million, up from $167 million in 2024, with core revenue at $240 million reflecting a 43% year-over-year growth [12][13] - Full-year adjusted EPS increased to $8.13, a 42% rise year-over-year, driven by strong operating leverage and higher royalty contributions [13][10] - Royalty revenue grew to $161 million, marking a 48% increase year-over-year, primarily from FILSPARI, Ohtuvayre, CAPVAXIVE, and QARZIBA [12][5] Business Line Performance - FILSPARI's U.S. net sales reached $103 million in Q4, representing 108% growth year-over-year, with total global sales of approximately $355 million for 2025 [13][14] - Ohtuvayre reported U.S. net sales of $506 million for the full year 2025, with Q4 sales of nearly $200 million [14] - CAPVAXIVE's net sales were $279 million in Q4 and $755 million for the full year, nearing blockbuster status [15] Market Data - The royalty financing market has doubled over the last five years, indicating a growing demand for royalty capital [9] - Ligand expects a compound annual growth rate of 23% in royalty receipts from 2025 through 2030, driven by contributions across its portfolio [10] Company Strategy and Industry Competition - Ligand is focusing on disciplined investments to create new royalty streams and enhance long-term shareholder value, with a strong emphasis on proactive portfolio management [6][19] - The company is positioned uniquely within the biopharmaceutical royalty financing sector, capitalizing on high demand for capital [9] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the continued momentum of the royalty portfolio and the disciplined capital deployment approach, which positions the company for sustained long-term growth [11][33] - The company anticipates a strong pipeline of late-stage development programs and is optimistic about upcoming regulatory decisions and market expansions [33][27] Other Important Information - Ligand ended 2025 with $734 million in cash equivalents and short-term investments, totaling over $1 billion in deployable capital [17] - The company is actively engaged in monetizing older assets and exploring new investment opportunities across its portfolio [41][42] Q&A Session Summary Question: Clinical update expectations for late-stage royalty portfolio - Management highlighted several active late-stage programs, including QARZIBA and Lasofoxifene, with robust updates expected in the coming quarters [37] Question: Update on monetizing older assets - Management confirmed ongoing engagement with 5 to 10 opportunities for monetization and expects announcements by year-end [41] Question: Market opportunity for TZIELD - Management acknowledged the low royalty but emphasized the potential blockbuster opportunity with Sanofi's TZIELD, particularly in Stage 3 Type 1 diabetes [46] Question: Impact of FSGS approval delay on 2026 outlook - Management indicated that the FSGS approval delay would have a negligible impact on the 2026 guidance, with a modest $4 million contribution assumed [51][63] Question: Differentiation of Castle Creek technology - Management discussed the potential advantages of the Castle Creek treatment over competitors, emphasizing its injectable nature and broader application [58]

Fourth Quarter and Full Year 2025 Financial Results F E B R U A R Y 2 6 , 2 0 2 6 | FINANCIAL | 48% Full-year royalty revenue growth over 2024 | | --- | --- | | Strong financial performance | 42% Full-year core adjusted EPS growth to $8.131 per share | | BUSINESS DEVELOPMENT | Scaling the BD function to capture value from our deep investment pipeline | | Highly productive, rigorous process | ~$1B Deployable capital (including credit facility) | | | Positions us for continued growth and expansion across our ...

Core Insights - Denali Therapeutics and Royalty Pharma have entered into a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa, Denali's lead investigational therapy for mucopolysaccharidosis type II (MPS II) [1][4] - The FDA is currently reviewing a Biologics License Application (BLA) for accelerated approval of tividenofusp alfa, with a target date of April 5, 2026 [2] Company Overview - Denali Therapeutics is focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle platform, aiming to address serious diseases including neurodegenerative and lysosomal storage disorders [6] - Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to leading pharmaceutical companies [7] Transaction Details - The agreement stipulates an initial payment of $200 million from Royalty Pharma, with an additional $75 million contingent upon achieving EMA approval by December 31, 2029 [4] - Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, with payments ceasing upon reaching a multiple of 3.0x or 2.5x if achieved by Q1 2039 [4] Leadership Statements - Denali's CEO, Ryan Watts, expressed optimism about the partnership with Royalty Pharma, highlighting the potential of tividenofusp alfa for the Hunter community and the broader implications for the TransportVehicle platform [3] - Royalty Pharma's CEO, Pablo Legorreta, emphasized the innovative nature of tividenofusp alfa and its potential to address significant unmet needs in Hunter syndrome [3]

Summary of Ultragenyx Pharmaceutical FY Conference Call Company Overview - **Company**: Ultragenyx Pharmaceutical (NasdaqGS:RARE) - **Focus**: Development and commercialization of drugs for patients with rare diseases, particularly Osteogenesis Imperfecta (OI) and Angelman syndrome [2][26] Key Points Product Pipeline and Development - **Current Products**: Success with Crysvita, supported by Mepsevii, Evkeeza, and Dojolvi [2] - **Upcoming Data**: Anticipation for phase three data readouts, particularly for Osteogenesis Imperfecta [2] - **Setrusumab**: Expected to show significant results in both Orbit and Cosmic studies, with a focus on the probability of success [5][6] Financial Strategy - **Royalty Financing**: Initiated due to the delay in potential revenue from the Sanfilippo program, allowing for a stronger balance sheet without diluting stock [3] Clinical Trials - **Orbit and Cosmic Studies**: Both studies are designed to be reported together, with confidence in their success [4] - **Effect Size Expectations**: A treatment effect size of 30% to 40% is considered clinically meaningful, with a powered expectation of at least 50% [6][7] - **Rescue Treatment Protocol**: Ethical considerations in allowing patients to receive rescue treatment if they experience high fracture rates [9][10] Commercial Considerations - **Pricing Strategy**: Pricing for Osteogenesis Imperfecta will be informed by the successful launch of Crysvita [11] - **Duration of Treatment**: Setrusumab is expected to be a lifelong treatment due to its mechanism of action [12] Patient Demographics - **Trial Composition**: Orbit phase three includes approximately 50% type 3 and 4 patients, with a commercial mix of about 60% type 1 and 38% type 3 and 4 patients [14][15] Confidence in Data - **Confidence Level**: High confidence in the upcoming data readout for Setrusumab, supported by consistent results in earlier phases [16] Angelman Syndrome Program - **Phase 1/2 Study**: Enrollment of 74 patients, with ongoing discussions about data release prior to the next phase [17] - **Safety Monitoring**: Close monitoring of lower extremity weakness, with mild cases reported and resolved quickly [18][19] - **Dropout Rates**: Expected to remain low due to the nature of the study and the potential benefits for patients [19] Developmental Outcomes - **Cognitive Improvement**: Unique potential to improve cognition and communication in patients with Angelman syndrome, rather than just preventing deterioration [22] - **Primary Endpoint Focus**: Cognition is the primary endpoint, followed by communication and motor skills [25] Future Outlook - **Gene Therapy Programs**: Continued focus on gene therapy programs, with upcoming PDUFA dates for Sanfilippo and GSD1A expected to lead to successful launches [26]

Core Insights - Ultragenyx Pharmaceutical Inc. has sold an additional 25% of its royalty interest in Crysvita® for $400 million to OMERS, a major Canadian pension plan, which will begin receiving this royalty in January 2028 [1][2] - The proceeds from this transaction will support four expected product launches and contribute to the company's growth strategy, aiming for full-year GAAP profitability by 2027 [2] - Crysvita® has generated over $4 billion in cumulative sales in the U.S. and Canada, treating more than 3,000 patients since its launch [2] Financial Details - The new agreement with OMERS caps total payments at 1.55 times the purchase price, following a previous agreement that capped payments at 1.45 times [1] - OMERS will continue to receive 30% of Crysvita® net sales in the U.S. and Canada after the previous agreement's cap is reached [1] Company Background - Ultragenyx is focused on developing therapies for serious rare and ultra-rare genetic diseases, with a diverse portfolio of approved medicines and treatment candidates [4][5] - The company has a management team experienced in rare disease therapeutics and emphasizes efficient drug development [5] Partnership Insights - OMERS Life Sciences specializes in providing royalty financing and non-dilutive solutions to biopharma companies, aligning with its strategy of delivering steady, long-term returns to its members [6][7] - The partnership with Ultragenyx reflects OMERS' commitment to investing in the life sciences sector and supporting innovative treatments for rare diseases [2][6]

Core Viewpoint - BridgeBio Pharma has entered into a royalty financing agreement, selling a portion of its royalties from BEYONTTRA sales in Europe for $300 million, which will provide immediate capital to support its operations and product launches [1][2][4]. Financial Details - The agreement allows BridgeBio to receive $300 million in exchange for 60% of royalties on the first $500 million of annual BEYONTTRA net sales in Europe, with total payments capped at 1.45 times the initial investment [3][4]. - BridgeBio has previously received $210 million in upfront and regulatory milestone payments from Bayer for BEYONTTRA and anticipates an additional $75 million in near-term milestone payments [4]. Product Information - BEYONTTRA is an orally administered stabilizer of transthyretin (TTR) for treating wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) [6][8]. - Acoramidis, the active ingredient in BEYONTTRA, has shown significant clinical benefits, including a 42% reduction in composite adverse cardiovascular events and a 50% reduction in cumulative frequency of cardiovascular events at 30 months compared to placebo [6]. Strategic Partnerships - The partnership with HealthCare Royalty and Blue Owl Capital is aimed at strengthening BridgeBio's balance sheet to support the launch of Attruby and its pipeline of genetic medicines [2][3]. - HCRx has expressed confidence in the commercial potential of BEYONTTRA and is committed to supporting innovation in the biopharmaceutical industry through this investment [3].

Summary of Royalty Pharma Conference Call Company Overview - **Company**: Royalty Pharma - **Founded**: Approximately 30 years ago by CEO and founder Pablo Legeretta - **Business Model**: Focuses on buying existing royalty streams from hospitals, universities, and foundations, and creating synthetic royalties through investments in R&D programs [2][3][4] Financial Performance - **Revenue**: Generated approximately $3 billion in revenue last year [5] - **EBITDA Margin**: 92% [5] - **Capital Deployment**: Plans to deploy $2 billion to $2.5 billion annually [5][36] - **Historical Returns**: Unlevered returns historically around 12% to 13%, with higher returns when leverage is applied [6][7] Investment Thesis - **Advantages Over Pharma Companies**: Royalty Pharma is not burdened by existing therapeutic areas or manufacturing costs, allowing for nimbleness in investment decisions [7] - **Comparison to Asset Managers**: Royalty Pharma has a proven track record of generating returns, unlike many alternative asset managers who are currently challenged to deploy capital effectively [9] Market Environment and Policy Impact - **Diversification**: The company is diversified across various therapeutic areas and commercial sectors, which mitigates risks associated with policy changes [11] - **Tariffs**: Monitoring tariffs as they could impact net sales of drugs, but the company feels secure in its position [12] Strategic Integration - **Management Structure Change**: Transitioned from being externally managed to being fully integrated as a public company, which has positively impacted shareholder sentiment [14][17][19] Investment Process and Deal Flow - **Active Deal Funnel**: Last year, the company had 440 opportunities in its deal funnel, completing 7-8 deals worth approximately $3 billion [23][28] - **Focus on Post-Proof of Concept**: The company prefers investments in products that are post-proof of concept and beyond [22] - **Geographic Sourcing**: Operates globally, leveraging its permanent capital structure to engage in long-term investments without the pressure of short-term returns [43][46] Portfolio Composition - **Diverse Therapeutic Areas**: The portfolio includes royalties from oncology, neurology, cystic fibrosis, and inflammation, with a focus on marketed products [38][39] - **Future Opportunities**: Actively seeking large potential royalties from products in late-stage development, such as Prexalimab and olpasiran [40][41] Key Metrics and Future Outlook - **Capital Deployment Growth**: Historically, every billion dollars invested leads to approximately $150 million to $170 million in revenue five years later [31] - **Analyst Day**: Upcoming Analyst Day on September 11 may provide updated targets for capital deployment [34][36] Competitive Landscape - **Long-Term Relationships**: The company emphasizes the importance of relationships in securing deals, with a history of repeat transactions with partners [58][60] - **High Standards for Deals**: Maintains a high bar for deal selection to ensure attractive returns for shareholders [50] Conclusion - **Focus on Execution**: The company aims to continue executing its strategy of investing in high-quality assets that address unmet medical needs while generating reasonable returns for shareholders [65]